The effect of Vitilexine Cream Givrelle in comparison with placebo in the treatment of patients with vitiligo undergoing phototherapy

Evaluation of the effect of Vitilexine Cream Givrelle in comparison with placebo in the treatment of patients with vitiligo undergoing phototherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150825023753N21

Enrollment

Registered

2023-11-15

Start date

2023-11-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: One of the lesions located on one side of the body will receive Vitilexine Cream Givrelle twice a day for three months. Also, patients will be treated with narrowband ultraviolet B (nb

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient's age is over 18 years The presence of at least 2 vitiligo corneal lesions in the upper, lower limbs, face or trunk that are similar in size and color The disease is under control (non-progressive). Involvement of at least 10% of the body surface Patients willing to participate in the study

Exclusion criteria

Exclusion criteria: Use of topical medications in the last month Having an immune deficiency Any contraindication for phototherapy such as a history of skin cancer Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Severity of vitiligo. Timepoint: Before the intervention, 6 weeks later, 12 weeks later. Method of measurement: Vitiligo Area Scoring Index (VASI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Samaneh Yekran

Shiraz University of Medical Sciences

s_yekran@sums.ac.ir+98 71 3212 5592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026